FAK inhibition had anti-leukemia properties in Ph+ ALL and increased the cytotoxic effects of BCR-ABL1 inhibitors, such as dasatinib and nilotinib, in an in vivo mouse model. This evidence concerns the gene PTK2 and acute lymphoblastic leukemia.